What makes Capaxiv unique compared to other pneumococcal vaccines?

Capaxiv is the only vaccine that effectively protects against the pneumococcal strains responsible for 84% of invasive pneumococcal disease (IPD) in adults 50 or older. This provides significantly broader coverage compared to other pneumococcal conjugate vaccines, which only protect against up to 52% of these strains. However, safety precautions should be observed when considering Capaxiv. The vaccine should not be administered to individuals with allergies to the vaccine or its ingredients, and patients with weakened immune systems should consult their doctor before vaccination.